nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrazinamide—XDH—Carboplatin—testicular cancer	0.258	0.289	CbGbCtD
Pyrazinamide—XDH—Cisplatin—testicular cancer	0.221	0.247	CbGbCtD
Pyrazinamide—AOX1—Methotrexate—testicular cancer	0.166	0.186	CbGbCtD
Pyrazinamide—XDH—Doxorubicin—testicular cancer	0.148	0.166	CbGbCtD
Pyrazinamide—CYP3A4—Ifosfamide—testicular cancer	0.031	0.0347	CbGbCtD
Pyrazinamide—CYP1A2—Etoposide—testicular cancer	0.0283	0.0316	CbGbCtD
Pyrazinamide—CYP3A4—Vinblastine—testicular cancer	0.0164	0.0184	CbGbCtD
Pyrazinamide—CYP3A4—Etoposide—testicular cancer	0.0148	0.0166	CbGbCtD
Pyrazinamide—CYP3A4—Doxorubicin—testicular cancer	0.0101	0.0113	CbGbCtD
Pyrazinamide—Digestion impaired—Chlorambucil—testicular cancer	0.00309	0.0292	CcSEcCtD
Pyrazinamide—Peptic ulcer—Vinblastine—testicular cancer	0.00283	0.0268	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Chlorambucil—testicular cancer	0.00267	0.0253	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Chlorambucil—testicular cancer	0.00223	0.0211	CcSEcCtD
Pyrazinamide—Hepatomegaly—Dactinomycin—testicular cancer	0.00211	0.0199	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Chlorambucil—testicular cancer	0.0021	0.0199	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Dactinomycin—testicular cancer	0.00193	0.0183	CcSEcCtD
Pyrazinamide—Coagulopathy—Dactinomycin—testicular cancer	0.00191	0.0181	CcSEcCtD
Pyrazinamide—Tubulointerstitial nephritis—Ifosfamide—testicular cancer	0.00178	0.0169	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Ifosfamide—testicular cancer	0.00177	0.0167	CcSEcCtD
Pyrazinamide—Coagulopathy—Ifosfamide—testicular cancer	0.00175	0.0166	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Cisplatin—testicular cancer	0.00153	0.0144	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Etoposide—testicular cancer	0.0014	0.0132	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Cisplatin—testicular cancer	0.00127	0.012	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Cisplatin—testicular cancer	0.0012	0.0113	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Etoposide—testicular cancer	0.00116	0.011	CcSEcCtD
Pyrazinamide—Body temperature increased—Carboplatin—testicular cancer	0.00113	0.0107	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Etoposide—testicular cancer	0.0011	0.0104	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Etoposide—testicular cancer	0.000981	0.00928	CcSEcCtD
Pyrazinamide—Hepatomegaly—Epirubicin—testicular cancer	0.000854	0.00808	CcSEcCtD
Pyrazinamide—Hepatotoxicity—Methotrexate—testicular cancer	0.000837	0.00792	CcSEcCtD
Pyrazinamide—Dysuria—Ifosfamide—testicular cancer	0.000801	0.00758	CcSEcCtD
Pyrazinamide—Hepatomegaly—Doxorubicin—testicular cancer	0.000791	0.00748	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Vinblastine—testicular cancer	0.000768	0.00726	CcSEcCtD
Pyrazinamide—Hepatitis—Dactinomycin—testicular cancer	0.000749	0.00708	CcSEcCtD
Pyrazinamide—Malaise—Vinblastine—testicular cancer	0.000746	0.00706	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Chlorambucil—testicular cancer	0.000721	0.00682	CcSEcCtD
Pyrazinamide—Anorexia—Chlorambucil—testicular cancer	0.000702	0.00664	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Methotrexate—testicular cancer	0.000697	0.00659	CcSEcCtD
Pyrazinamide—Discomfort—Vinblastine—testicular cancer	0.000696	0.00658	CcSEcCtD
Pyrazinamide—Hepatitis—Ifosfamide—testicular cancer	0.000686	0.00649	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Vinblastine—testicular cancer	0.000661	0.00625	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Methotrexate—testicular cancer	0.000658	0.00623	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Epirubicin—testicular cancer	0.000652	0.00617	CcSEcCtD
Pyrazinamide—Dyspepsia—Chlorambucil—testicular cancer	0.000649	0.00614	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Bleomycin—testicular cancer	0.000648	0.00613	CcSEcCtD
Pyrazinamide—Anorexia—Vinblastine—testicular cancer	0.000644	0.00609	CcSEcCtD
Pyrazinamide—Decreased appetite—Chlorambucil—testicular cancer	0.000641	0.00606	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000636	0.00602	CcSEcCtD
Pyrazinamide—Malaise—Bleomycin—testicular cancer	0.00063	0.00596	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Epirubicin—testicular cancer	0.000616	0.00583	CcSEcCtD
Pyrazinamide—Feeling abnormal—Chlorambucil—testicular cancer	0.000607	0.00574	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Dactinomycin—testicular cancer	0.000605	0.00572	CcSEcCtD
Pyrazinamide—Hyperuricaemia—Doxorubicin—testicular cancer	0.000603	0.00571	CcSEcCtD
Pyrazinamide—Myalgia—Bleomycin—testicular cancer	0.000595	0.00563	CcSEcCtD
Pyrazinamide—Discomfort—Bleomycin—testicular cancer	0.000588	0.00556	CcSEcCtD
Pyrazinamide—Malaise—Dactinomycin—testicular cancer	0.000588	0.00556	CcSEcCtD
Pyrazinamide—Decreased appetite—Vinblastine—testicular cancer	0.000587	0.00555	CcSEcCtD
Pyrazinamide—Urticaria—Chlorambucil—testicular cancer	0.000585	0.00554	CcSEcCtD
Pyrazinamide—Body temperature increased—Chlorambucil—testicular cancer	0.000582	0.00551	CcSEcCtD
Pyrazinamide—Blood uric acid increased—Doxorubicin—testicular cancer	0.00057	0.00539	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Bleomycin—testicular cancer	0.000558	0.00528	CcSEcCtD
Pyrazinamide—Feeling abnormal—Vinblastine—testicular cancer	0.000556	0.00526	CcSEcCtD
Pyrazinamide—Myalgia—Dactinomycin—testicular cancer	0.000555	0.00525	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Ifosfamide—testicular cancer	0.000554	0.00524	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Epirubicin—testicular cancer	0.00055	0.0052	CcSEcCtD
Pyrazinamide—Discomfort—Dactinomycin—testicular cancer	0.000548	0.00519	CcSEcCtD
Pyrazinamide—Anorexia—Bleomycin—testicular cancer	0.000544	0.00514	CcSEcCtD
Pyrazinamide—Hypersensitivity—Chlorambucil—testicular cancer	0.000543	0.00514	CcSEcCtD
Pyrazinamide—Malaise—Ifosfamide—testicular cancer	0.000539	0.00509	CcSEcCtD
Pyrazinamide—Photosensitivity—Methotrexate—testicular cancer	0.000534	0.00505	CcSEcCtD
Pyrazinamide—Pruritus—Chlorambucil—testicular cancer	0.000521	0.00493	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Dactinomycin—testicular cancer	0.000521	0.00493	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00052	0.00492	CcSEcCtD
Pyrazinamide—Rash maculo-papular—Doxorubicin—testicular cancer	0.000509	0.00481	CcSEcCtD
Pyrazinamide—Myalgia—Ifosfamide—testicular cancer	0.000508	0.00481	CcSEcCtD
Pyrazinamide—Arthralgia—Ifosfamide—testicular cancer	0.000508	0.00481	CcSEcCtD
Pyrazinamide—Anorexia—Dactinomycin—testicular cancer	0.000507	0.0048	CcSEcCtD
Pyrazinamide—Discomfort—Ifosfamide—testicular cancer	0.000502	0.00475	CcSEcCtD
Pyrazinamide—Photosensitivity—Epirubicin—testicular cancer	0.0005	0.00473	CcSEcCtD
Pyrazinamide—Hypersensitivity—Vinblastine—testicular cancer	0.000497	0.00471	CcSEcCtD
Pyrazinamide—Decreased appetite—Bleomycin—testicular cancer	0.000496	0.00469	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000485	0.00458	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Cisplatin—testicular cancer	0.000478	0.00452	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Ifosfamide—testicular cancer	0.000477	0.00451	CcSEcCtD
Pyrazinamide—Feeling abnormal—Bleomycin—testicular cancer	0.00047	0.00445	CcSEcCtD
Pyrazinamide—Vomiting—Chlorambucil—testicular cancer	0.000468	0.00443	CcSEcCtD
Pyrazinamide—Anorexia—Ifosfamide—testicular cancer	0.000465	0.00439	CcSEcCtD
Pyrazinamide—Malaise—Cisplatin—testicular cancer	0.000464	0.00439	CcSEcCtD
Pyrazinamide—Photosensitivity—Doxorubicin—testicular cancer	0.000463	0.00438	CcSEcCtD
Pyrazinamide—Decreased appetite—Dactinomycin—testicular cancer	0.000462	0.00437	CcSEcCtD
Pyrazinamide—Urticaria—Bleomycin—testicular cancer	0.000453	0.00429	CcSEcCtD
Pyrazinamide—Body temperature increased—Bleomycin—testicular cancer	0.000451	0.00426	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000444	0.0042	CcSEcCtD
Pyrazinamide—Myalgia—Cisplatin—testicular cancer	0.000438	0.00415	CcSEcCtD
Pyrazinamide—Feeling abnormal—Dactinomycin—testicular cancer	0.000438	0.00415	CcSEcCtD
Pyrazinamide—Nausea—Chlorambucil—testicular cancer	0.000438	0.00414	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Etoposide—testicular cancer	0.000438	0.00414	CcSEcCtD
Pyrazinamide—Discomfort—Cisplatin—testicular cancer	0.000433	0.0041	CcSEcCtD
Pyrazinamide—Vomiting—Vinblastine—testicular cancer	0.000429	0.00406	CcSEcCtD
Pyrazinamide—Malaise—Etoposide—testicular cancer	0.000425	0.00402	CcSEcCtD
Pyrazinamide—Decreased appetite—Ifosfamide—testicular cancer	0.000424	0.00401	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000421	0.00398	CcSEcCtD
Pyrazinamide—Body temperature increased—Dactinomycin—testicular cancer	0.00042	0.00398	CcSEcCtD
Pyrazinamide—Hypersensitivity—Bleomycin—testicular cancer	0.00042	0.00397	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Cisplatin—testicular cancer	0.000411	0.00389	CcSEcCtD
Pyrazinamide—Pruritus—Bleomycin—testicular cancer	0.000403	0.00382	CcSEcCtD
Pyrazinamide—Feeling abnormal—Ifosfamide—testicular cancer	0.000402	0.0038	CcSEcCtD
Pyrazinamide—Nausea—Vinblastine—testicular cancer	0.000401	0.00379	CcSEcCtD
Pyrazinamide—Anorexia—Cisplatin—testicular cancer	0.000401	0.00379	CcSEcCtD
Pyrazinamide—Discomfort—Etoposide—testicular cancer	0.000397	0.00375	CcSEcCtD
Pyrazinamide—Hypersensitivity—Dactinomycin—testicular cancer	0.000392	0.00371	CcSEcCtD
Pyrazinamide—Urticaria—Ifosfamide—testicular cancer	0.000387	0.00366	CcSEcCtD
Pyrazinamide—Body temperature increased—Ifosfamide—testicular cancer	0.000385	0.00364	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000383	0.00362	CcSEcCtD
Pyrazinamide—Dysuria—Methotrexate—testicular cancer	0.000379	0.00359	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Etoposide—testicular cancer	0.000377	0.00357	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Methotrexate—testicular cancer	0.00037	0.0035	CcSEcCtD
Pyrazinamide—Anorexia—Etoposide—testicular cancer	0.000367	0.00347	CcSEcCtD
Pyrazinamide—Decreased appetite—Cisplatin—testicular cancer	0.000365	0.00346	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000363	0.00343	CcSEcCtD
Pyrazinamide—Vomiting—Bleomycin—testicular cancer	0.000363	0.00343	CcSEcCtD
Pyrazinamide—Rash—Bleomycin—testicular cancer	0.00036	0.0034	CcSEcCtD
Pyrazinamide—Dermatitis—Bleomycin—testicular cancer	0.000359	0.0034	CcSEcCtD
Pyrazinamide—Hypersensitivity—Ifosfamide—testicular cancer	0.000359	0.0034	CcSEcCtD
Pyrazinamide—Dysuria—Epirubicin—testicular cancer	0.000355	0.00336	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Epirubicin—testicular cancer	0.000346	0.00328	CcSEcCtD
Pyrazinamide—Feeling abnormal—Cisplatin—testicular cancer	0.000346	0.00328	CcSEcCtD
Pyrazinamide—Pruritus—Ifosfamide—testicular cancer	0.000345	0.00326	CcSEcCtD
Pyrazinamide—Nausea—Bleomycin—testicular cancer	0.000339	0.0032	CcSEcCtD
Pyrazinamide—Vomiting—Dactinomycin—testicular cancer	0.000338	0.0032	CcSEcCtD
Pyrazinamide—Rash—Dactinomycin—testicular cancer	0.000335	0.00317	CcSEcCtD
Pyrazinamide—Decreased appetite—Etoposide—testicular cancer	0.000335	0.00317	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Etoposide—testicular cancer	0.000332	0.00314	CcSEcCtD
Pyrazinamide—Body temperature increased—Cisplatin—testicular cancer	0.000332	0.00314	CcSEcCtD
Pyrazinamide—Dysuria—Doxorubicin—testicular cancer	0.000328	0.00311	CcSEcCtD
Pyrazinamide—Hepatitis—Methotrexate—testicular cancer	0.000325	0.00307	CcSEcCtD
Pyrazinamide—Photosensitivity reaction—Doxorubicin—testicular cancer	0.00032	0.00303	CcSEcCtD
Pyrazinamide—Feeling abnormal—Etoposide—testicular cancer	0.000317	0.003	CcSEcCtD
Pyrazinamide—Nausea—Dactinomycin—testicular cancer	0.000316	0.00299	CcSEcCtD
Pyrazinamide—Vomiting—Ifosfamide—testicular cancer	0.00031	0.00293	CcSEcCtD
Pyrazinamide—Hypersensitivity—Cisplatin—testicular cancer	0.00031	0.00293	CcSEcCtD
Pyrazinamide—Rash—Ifosfamide—testicular cancer	0.000307	0.00291	CcSEcCtD
Pyrazinamide—Dermatitis—Ifosfamide—testicular cancer	0.000307	0.0029	CcSEcCtD
Pyrazinamide—Urticaria—Etoposide—testicular cancer	0.000306	0.00289	CcSEcCtD
Pyrazinamide—Body temperature increased—Etoposide—testicular cancer	0.000304	0.00288	CcSEcCtD
Pyrazinamide—Hepatitis—Epirubicin—testicular cancer	0.000304	0.00287	CcSEcCtD
Pyrazinamide—Nausea—Ifosfamide—testicular cancer	0.00029	0.00274	CcSEcCtD
Pyrazinamide—Hypersensitivity—Etoposide—testicular cancer	0.000284	0.00268	CcSEcCtD
Pyrazinamide—Hepatitis—Doxorubicin—testicular cancer	0.000281	0.00266	CcSEcCtD
Pyrazinamide—Pruritus—Etoposide—testicular cancer	0.000272	0.00258	CcSEcCtD
Pyrazinamide—Vomiting—Cisplatin—testicular cancer	0.000267	0.00253	CcSEcCtD
Pyrazinamide—Rash—Cisplatin—testicular cancer	0.000265	0.00251	CcSEcCtD
Pyrazinamide—Dermatitis—Cisplatin—testicular cancer	0.000265	0.0025	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Methotrexate—testicular cancer	0.000262	0.00248	CcSEcCtD
Pyrazinamide—Malaise—Methotrexate—testicular cancer	0.000255	0.00241	CcSEcCtD
Pyrazinamide—Nausea—Cisplatin—testicular cancer	0.00025	0.00236	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Epirubicin—testicular cancer	0.000245	0.00232	CcSEcCtD
Pyrazinamide—Vomiting—Etoposide—testicular cancer	0.000245	0.00232	CcSEcCtD
Pyrazinamide—Rash—Etoposide—testicular cancer	0.000243	0.0023	CcSEcCtD
Pyrazinamide—Dermatitis—Etoposide—testicular cancer	0.000242	0.00229	CcSEcCtD
Pyrazinamide—Arthralgia—Methotrexate—testicular cancer	0.000241	0.00228	CcSEcCtD
Pyrazinamide—Myalgia—Methotrexate—testicular cancer	0.000241	0.00228	CcSEcCtD
Pyrazinamide—Malaise—Epirubicin—testicular cancer	0.000238	0.00226	CcSEcCtD
Pyrazinamide—Discomfort—Methotrexate—testicular cancer	0.000238	0.00225	CcSEcCtD
Pyrazinamide—Nausea—Etoposide—testicular cancer	0.000229	0.00216	CcSEcCtD
Pyrazinamide—Ill-defined disorder—Doxorubicin—testicular cancer	0.000227	0.00215	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Methotrexate—testicular cancer	0.000226	0.00214	CcSEcCtD
Pyrazinamide—Myalgia—Epirubicin—testicular cancer	0.000225	0.00213	CcSEcCtD
Pyrazinamide—Arthralgia—Epirubicin—testicular cancer	0.000225	0.00213	CcSEcCtD
Pyrazinamide—Discomfort—Epirubicin—testicular cancer	0.000222	0.0021	CcSEcCtD
Pyrazinamide—Malaise—Doxorubicin—testicular cancer	0.000221	0.00209	CcSEcCtD
Pyrazinamide—Anorexia—Methotrexate—testicular cancer	0.00022	0.00208	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Epirubicin—testicular cancer	0.000211	0.002	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00021	0.00199	CcSEcCtD
Pyrazinamide—Arthralgia—Doxorubicin—testicular cancer	0.000208	0.00197	CcSEcCtD
Pyrazinamide—Myalgia—Doxorubicin—testicular cancer	0.000208	0.00197	CcSEcCtD
Pyrazinamide—Discomfort—Doxorubicin—testicular cancer	0.000206	0.00195	CcSEcCtD
Pyrazinamide—Anorexia—Epirubicin—testicular cancer	0.000206	0.00195	CcSEcCtD
Pyrazinamide—Dyspepsia—Methotrexate—testicular cancer	0.000203	0.00192	CcSEcCtD
Pyrazinamide—Decreased appetite—Methotrexate—testicular cancer	0.0002	0.0019	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000199	0.00188	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000197	0.00186	CcSEcCtD
Pyrazinamide—Thrombocytopenia—Doxorubicin—testicular cancer	0.000195	0.00185	CcSEcCtD
Pyrazinamide—Anorexia—Doxorubicin—testicular cancer	0.00019	0.0018	CcSEcCtD
Pyrazinamide—Feeling abnormal—Methotrexate—testicular cancer	0.00019	0.0018	CcSEcCtD
Pyrazinamide—Dyspepsia—Epirubicin—testicular cancer	0.00019	0.0018	CcSEcCtD
Pyrazinamide—Decreased appetite—Epirubicin—testicular cancer	0.000188	0.00177	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000186	0.00176	CcSEcCtD
Pyrazinamide—Urticaria—Methotrexate—testicular cancer	0.000183	0.00173	CcSEcCtD
Pyrazinamide—Body temperature increased—Methotrexate—testicular cancer	0.000182	0.00172	CcSEcCtD
Pyrazinamide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000182	0.00172	CcSEcCtD
Pyrazinamide—Feeling abnormal—Epirubicin—testicular cancer	0.000178	0.00168	CcSEcCtD
Pyrazinamide—Dyspepsia—Doxorubicin—testicular cancer	0.000176	0.00166	CcSEcCtD
Pyrazinamide—Decreased appetite—Doxorubicin—testicular cancer	0.000174	0.00164	CcSEcCtD
Pyrazinamide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000172	0.00163	CcSEcCtD
Pyrazinamide—Urticaria—Epirubicin—testicular cancer	0.000171	0.00162	CcSEcCtD
Pyrazinamide—Body temperature increased—Epirubicin—testicular cancer	0.000171	0.00161	CcSEcCtD
Pyrazinamide—Hypersensitivity—Methotrexate—testicular cancer	0.00017	0.00161	CcSEcCtD
Pyrazinamide—Feeling abnormal—Doxorubicin—testicular cancer	0.000165	0.00156	CcSEcCtD
Pyrazinamide—Pruritus—Methotrexate—testicular cancer	0.000163	0.00154	CcSEcCtD
Pyrazinamide—Hypersensitivity—Epirubicin—testicular cancer	0.000159	0.0015	CcSEcCtD
Pyrazinamide—Urticaria—Doxorubicin—testicular cancer	0.000159	0.0015	CcSEcCtD
Pyrazinamide—Body temperature increased—Doxorubicin—testicular cancer	0.000158	0.00149	CcSEcCtD
Pyrazinamide—Pruritus—Epirubicin—testicular cancer	0.000153	0.00144	CcSEcCtD
Pyrazinamide—Hypersensitivity—Doxorubicin—testicular cancer	0.000147	0.00139	CcSEcCtD
Pyrazinamide—Vomiting—Methotrexate—testicular cancer	0.000147	0.00139	CcSEcCtD
Pyrazinamide—Rash—Methotrexate—testicular cancer	0.000145	0.00138	CcSEcCtD
Pyrazinamide—Dermatitis—Methotrexate—testicular cancer	0.000145	0.00137	CcSEcCtD
Pyrazinamide—Pruritus—Doxorubicin—testicular cancer	0.000141	0.00134	CcSEcCtD
Pyrazinamide—Vomiting—Epirubicin—testicular cancer	0.000137	0.0013	CcSEcCtD
Pyrazinamide—Nausea—Methotrexate—testicular cancer	0.000137	0.0013	CcSEcCtD
Pyrazinamide—Rash—Epirubicin—testicular cancer	0.000136	0.00129	CcSEcCtD
Pyrazinamide—Dermatitis—Epirubicin—testicular cancer	0.000136	0.00129	CcSEcCtD
Pyrazinamide—Nausea—Epirubicin—testicular cancer	0.000128	0.00121	CcSEcCtD
Pyrazinamide—Vomiting—Doxorubicin—testicular cancer	0.000127	0.0012	CcSEcCtD
Pyrazinamide—Rash—Doxorubicin—testicular cancer	0.000126	0.00119	CcSEcCtD
Pyrazinamide—Dermatitis—Doxorubicin—testicular cancer	0.000126	0.00119	CcSEcCtD
Pyrazinamide—Nausea—Doxorubicin—testicular cancer	0.000119	0.00112	CcSEcCtD
